Prognostic significance of the neutrophil-to-lymphocyte ratio in esophageal squamous cell carcinoma treated with proton beam therapy
Radiation Oncology Journal · 31.03.2026 · 44 (1) · 28-36
DOI: 10.3857/roj.2025.00654 ↗Kurz gefasst
Fachartikel in der Zeitschrift Radiation Oncology Journal, erschienen am 31.03.2026. Verfasst von Kenji Makita und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, National Cancer Center Hospital East, Kashiwa, Japan. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
This study evaluated the impact of neutrophil-to-lymphocyte ratio on the survival of patients with esophageal squamous cell carcinoma (ESCC) who underwent proton beam therapy with concurrent chemotherapy. Materials and Methods: Data of patients with ESCC who received definitive proton beam therapy with concurrent chemotherapy between January 2015 and January 2020 were retrospectively analysed. The 3-year overall and progression-free survival rates were calculated. Prognostic factors, including neutrophil-to-lymphocyte ratio, were examined.
Results
In total, 116 consecutive patients with ESCC (median age, 68 years; range, 45 to 90 years) were included. The median follow-up time was 51.2 months (range, 3.0 to 114.0). Complete clinical response was observed in 75 patients (64.7%). The 3-year overall and progression-free survival rates were 82.4% and 59.4%, respectively. In a multivariate analysis, a Eastern Cooperative Oncology Group performance status ≥1 (hazard ratio [HR], 2.52; 95% confidence interval [CI], 1.00 to 6.34; p = 0.049), clinical stage Ⅳ disease according to the Union for International Cancer Control 8th edition (HR, 3.37; 95% CI, 1.30 to 8.77; p = 0.013), and a neutrophil-to-lymphocyte ratio ≥3.00 (HR, 3.89; 95% CI, 1.36 to 11.19; p = 0.012) were significantly associated with poorer overall survival. Clinical stage Ⅳ disease (HR, 2.86; 95% CI, 1.50 to 5.44; p = 0.003) and neutrophil-to-lymphocyte ratio ≥3.00 (HR, 2.40; 95% CI, 1.32 to 4.39; p = 0.004) were significantly associated with poorer progression-free survival.
Conclusion
In patients with ESCC who received definitive proton beam therapy with concurrent chemotherapy, a high neutrophil-to-lymphocyte ratio was a significant poor prognostic factor for both overall and progression-free survival.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
- Department of Radiation Oncology, NHO Shikoku Cancer Center, Matsuyama, Japan.
- Department of Radiotherapy, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
- Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
- Biostatistics Division, Center for Research Administration and Support, National Cancer Center Hospital East, Kashiwa, Japan.
Zitieren
APA
Makita, K., Hojo, H., Hirata, H., Dey, T., Nakamura, M., Fujisawa, T., Kotani, D., Wakabayashi, M., Oyoshi, H., Tomizawa, K., Zhou, Y., Koike, Y., Uchida, G., Mishima, S., Kojima, T., & Zenda, S. (2026). Prognostic significance of the neutrophil-to-lymphocyte ratio in esophageal squamous cell carcinoma treated with proton beam therapy. Radiation Oncology Journal, 44(1), 28-36. https://doi.org/10.3857/roj.2025.00654
Vancouver
Makita K, Hojo H, Hirata H, Dey T, Nakamura M, Fujisawa T, et al. Prognostic significance of the neutrophil-to-lymphocyte ratio in esophageal squamous cell carcinoma treated with proton beam therapy. Radiation Oncology Journal. 2026;44(1):28-36. doi:10.3857/roj.2025.00654
BibTeX
@article{Makita2026,
author = {Makita, Kenji and Hojo, Hidehiro and Hirata, Hidenari and Dey, Treshita and Nakamura, Masaki and Fujisawa, Takeshi and Kotani, Daisuke and Wakabayashi, Masashi and Oyoshi, Hidekazu and Tomizawa, Kento and Zhou, Yuzheng and Koike, Yume and Uchida, Gyo and Mishima, Saori and Kojima, Takashi and Zenda, Sadamoto},
title = {Prognostic significance of the neutrophil-to-lymphocyte ratio in esophageal squamous cell carcinoma treated with proton beam therapy},
journal = {Radiation Oncology Journal},
year = {2026},
volume = {44},
number = {1},
pages = {28--36},
doi = {10.3857/roj.2025.00654}
}
EUVIMED